1'-(Anthracene-9-carbonyl)-[1,4']bipiperidinyl-3-carboxylic acid amide | 591778-84-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: 1'-(Anthracene-9-carbonyl)-[1,4']bipiperidinyl-3-carboxylic acid amide
• 英文别名: 1-[1-(Anthracene-9-carbonyl)piperidin-4-yl]piperidine-3-carboxamide
• CAS: 591778-84-6
• 化学式: C₂₆H₂₉N₃O₂
• 分子量: 415.535
• InChiKey: LSVBREPOWZVKPL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  31
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  66.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Acetyl-CoA carboxylase inhibitors
  申请人：Pfizer Inc.

  公开号：US20030187254A1

  公开（公告）日：2003-10-02

  Acetyl Coenzyme A Carboxylase inhibitors, pharmaceutical compositions containing such compounds and the use of such compounds to treat for example, Metabolic Syndrome including atherosclerosis, diabetes and obesity.

  乙酰辅酶A羧化酶抑制剂，含有此类化合物的药物组合物，以及使用此类化合物治疗代谢综合征，包括动脉粥样硬化、糖尿病和肥胖等疾病。
• ACC INHIBITORS
  申请人：Pfizer Products Inc.

  公开号：EP1478437B1

  公开（公告）日：2005-08-31
• US6979741B2
  申请人：——

  公开号：US6979741B2

  公开（公告）日：2005-12-27
• [EN] TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS<br/>[FR] TRAITEMENT D'INFECTIONS VIRALES PAR MODULATION DE VOIES MÉTABOLIQUES DE CELLULES HÔTES
  申请人：UNIV PRINCETON

  公开号：WO2009023059A2

  公开（公告）日：2009-02-19

  Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in 'suicide' of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.